ADVESYA
Advesya is a biotechnology company focused on developing innovative therapies for challenging cancers. With a commitment to improving patient outcomes, Advesya leverages expertise in biochemistry, molecular and cellular biology, particularly in the fields of immuno-oncology and hematological malignancies. The company emphasizes the importance of privacy and data protection in its operations. Advesya's approach combines gene and cell therapy research with a dedication to creating new treatment options for cancers that are currently difficult to treat. Through its work, Advesya aims to contribute significantly to the advancement of cancer therapy.
ADVESYA
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2020-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.advesya.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Similar Organizations
Tesu Health
Tesu Health offers digital therapeutics for chronic diseases, focusing on non-chemical, non-biological treatments.
Official Site Inspections
http://www.advesya.com Semrush global rank: 14.73 M Semrush visits lastest month: 37
- Host name: galaxy.jabatus.com
- IP address: 109.234.166.45
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Advesya"
Advesya - Transforming cancer and autoimmune …
Nov 7, 2024 Advesya, a French/Swiss clinical-stage biotech company founded in 2020, is transforming the fight against cancer and autoimmune diseases. Building on years of academic research, advesya’s innovative work targets IL …See details»
Advesya - Crunchbase Company Profile & Funding
Advesya is a biotechnology company focused on developing innovative therapies for challenging cancers. With a commitment to improving patient outcomes, Advesya leverages expertise in biochemistry, molecular and cellular biology, …See details»
Advesya : a French/Swiss clinical-stage biotech company
Advesya, founded in 2020, is transforming the fight against cancer and autoimmune diseases. Advesya is a spin-out from the French Blood Institute (EFS) in Besançon (France). ... M&A, …See details»
Advesya - LinkedIn
Advesya | 1,350 followers on LinkedIn. Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches | Advesya is a pioneering and transformative …See details»
Advesya Company Profile 2024: Valuation, Funding
Advesya General Information Description. Provider of biotechnology services intended to treat cancers. The company specializes in aiding refractory acute myeloid leukemia patients as well as hematological malignancies, thereby …See details»
Advesya - Company Profile - Tracxn
Dec 6, 2024 Advesya - Developer of therapies for the treatment of cancer and autoimmune diseases. Raised a total funding of $26.1M over 1 round from 1 investor. Founded by …See details»
ADVESYA - Societe.com
Dec 22, 2023 ADVESYA, société par actions simplifiée, au capital social de 1020000,00 EURO, dont le siège social est situé au 25 RUE DU QUATRE SEPTEMBRE, 75002 PARIS, …See details»
ADVESYA AG Company Profile | Basel, BASEL-STADT, Switzerland ...
Find company research, competitor information, contact details & financial data for ADVESYA AG of Basel, BASEL-STADT. Get the latest business insights from Dun & Bradstreet.See details»
Advesya - Contacts, Employees, Board Members, Advisors & Alumni
Advesya specializes in developing therapies for difficult-to-treat cancers, focusing on immuno-oncology and hematological malignancies.See details»
Contact Us - Advesya
Building on years of academic research, advesya’s innovative work targets IL-1RAP, a unique antigen that is upregulated in various cancers. Skip to content. Our Company. Who we are; …See details»
Advesya Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Advesya Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 1 news, Disease Domain:Neoplasms, Hemic and Lymphatic Diseases, Technology …See details»
Jeito Capital portfolio company Advesya emerges from stealth …
Paris, France, 3 January 2024 – Jeito Capital (“Jeito”), a global leading independent private equity fund dedicated to biopharma, is pleased to announce the un-stealthing [1] of its portfolio …See details»
Advesya - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Jul 15, 2024 Organization. Advesya . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 3. Monthly Visits 37. …See details»
Advesya
Advesya is a pioneering and transformative biotechnology company founded in 2020. It is our mission and life purpose to help patients in their battle against cancer. We promise to …See details»
Advesya Company Profile | København Ø, Hovedstaden, Denmark ...
Find company research, competitor information, contact details & financial data for Advesya of København Ø, Hovedstaden. Get the latest business insights from Dun & Bradstreet.See details»
advesya - Tech Park Basel
Advesya. Advesya aims to develop and commercialise CAR-T cell therapies focusing on haematology and oncology, targeting acute myeloid leukaemia (AML) based on a first-in-class …See details»
Advesya | BIO-Europe Spring - Informa Connect
Advesya is a French-Swiss startup biotech. The company is focusing on IL-1RAP as a pathway and our most advanced program (a CAR-T in AML) is going into clinic very soon. Our second …See details»
Our pipeline - Advesya : transforming the fight against cancer
Building on years of academic research, advesya’s innovative work targets IL-1RAP, a unique antigen, which is upregulated in various cancers and autoimmune conditions. Skip to content. …See details»
Our Science - Advesya, clinical-stage biotech company
ADV-101 is a first-in-class ADC composed of Advesya’s proprietary humanized IgG1 monoclonal antibody that binds to human IL-1RAP. ADV-101 is conjugated to a cleavable linker with a …See details»
News - Advesya
Jul 11, 2024 Advesya to present two posters at #ASH24 Paris, France – Advesya, a company dedicated to developing novel therapies targeting IL-1RAP, announced that it will present two …See details»